Drug intelligence / Profile preview

Tenoros

Development stage: Unknown
Lead developer: Pharmaselect International
Modality: Small Molecules
Administration: Oral

Overview

Tenoros is a dietary supplement and food for special medical purposes (FSMP) developed by Pharmaselect International for the dietary management of weakened immune defenses during nasal infections, such as the common cold and runny nose. The product is formulated as lemon-flavored lozenges containing a patented, highly concentrated buckwheat (*Fagopyrum esculentum*) bioflavonoid extract known as PSI 265, combined with zinc gluconate. The bioflavonoids are designed to seal blood vessels and reduce nasal discharge and swelling without irritating the mucous membranes, while also promoting the action of interferon to support the body's natural defenses. Zinc gluconate provides additional support for normal immune system function.

Brand names: TenorosTenoros Nasenzuckerl

Targets

IFNL3 (Interferon lambda 3)

Beyond the preview

Go deeper on Tenoros.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tenoros.

Explore the full profile